Q/C Technologies, Inc.
QCLS- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001321834
No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Q/C Technologies, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 41 | 35 | −6 |
| Shares | 4.47M | 4.81M | +343.4K (+7.7%) |
| Value | $27.1M | $22.4M | −$4.65M (−17.2%) |
New holders (4)
Institutions that held Q/C Technologies, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| M Holdings Securities, Inc. | 70,909 | $330.0K | 0.02% |
| Western Wealth Management, LLC | 30,713 | $143.0K | 0.01% |
| Barclays PLC | 6,243 | $29.0K | 0.00% |
| Geneos Wealth Management Inc. | 500 | $2.00K | 0.00% |
Sold out (10)
Institutions that held Q/C Technologies, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Millennium Management LLC | 61,470 | $373.0K |
| Jane Street Group, LLC | 17,908 | $109.0K |
| Taylor & Morgan Wealth Management, LLC | 17,836 | $108.0K |
| Goldman Sachs Group Inc | 16,194 | $98.0K |
| HRT Financial LP | 15,851 | $96.0K |
| Ergoteles LLC | 11,800 | $72.0K |
| JPMorgan Chase & Co | 8,934 | $54.0K |
| UBS Group AG | 1,776 | $11.0K |
| Level Financial Advisors, Inc. | 200 | $1.00K |
| Cornerstone Advisory, LLC | 2 | $0 |